Floatz logo

108 assets in Prostate Carcinoma

Therapeutic assets addressing Prostate Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Exemestane
Prostate Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Fexagratinib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Fezolinetant
Prostate Carcinoma
Shehzad Basaria, M.D.P2CCC (53)
Furosemide
Prostate Carcinoma
Emory UniversityP2CCC (53)
Gadobutrol
Prostate Carcinoma
Northwestern UniversityP2CCC (53)
Gsk-2636771
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Histrelin
Prostate Carcinoma
Mayo ClinicP2CCC (53)
Ipatasertib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Nilutamide
Prostate Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Osimertinib
Prostate Carcinoma
OHSU Knight Cancer InstituteP2CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Prostate Carcinoma
University of WashingtonP2CCC (53)
Piflufolastat
Prostate Carcinoma
Northwestern UniversityP2CCC (53)
Relatlimab
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Sapanisertib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Semaglutide
Prostate Carcinoma
City of Hope Medical CenterP2CCC (53)
Talazoparib
Prostate Carcinoma
City of Hope Medical CenterP2CCC (53)
Teonanacatl
Prostate Carcinoma
Psyence Australia Pty LtdP2CCC (53)
Tirzepatide
Prostate Carcinoma
City of Hope Medical CenterP2CCC (53)
Trametinib
Prostate Carcinoma
Jonsson Comprehensive Cancer CenterP2CCC (53)
Tuvusertib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Ulixertinib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Zanzalintinib
Prostate Carcinoma
Deepak KilariP2CCC (53)
Adavosertib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (52)
Gadobenate Dimeglumine
Prostate Carcinoma
Northwestern UniversityP2CCC (51)
Taselisib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (51)
Copanlisib
Prostate Carcinoma
National Cancer Institute (NCI)P2CCC (49)
Fulvestrant
Prostate Carcinoma
Atavistik Bio, IncP1CCC (48)
Sinecatechins
Prostate Carcinoma
ECOG-ACRIN Cancer Research GroupP2CCC (48)
Cyclophosphamide
Prostate Carcinoma
Fred Hutchinson Cancer CenterP1CC (47)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Prostate Carcinoma
National Cancer Institute (NCI)P1/2CC (44)
225ac-psma-trillium
Prostate Carcinoma
BayerP1CC (43)
Actinium (225Ac) Psma-617
Prostate Carcinoma
Thomas HopeP1CC (43)
Dapagliflozin
Prostate Carcinoma
Washington University School of MedicineP1CC (43)
Lutetium Lu 177 Psma-10.1
Prostate Carcinoma
Emory UniversityP1CC (43)
Nuv-868
Prostate Carcinoma
Nuvation Bio Inc.P1CC (43)
Valemetostat
Prostate Carcinoma
M.D. Anderson Cancer CenterP1CC (43)
Atv-1601
Prostate Carcinoma
Atavistik Bio, IncP1CC (41)
Fapi-46
Prostate Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (41)
Fludarabine
Prostate Carcinoma
Fred Hutchinson Cancer CenterP1CC (41)
Alectinib
Prostate Carcinoma
OHSU Knight Cancer InstituteEarly P1C (39)
Alpelisib
Prostate Carcinoma
OHSU Knight Cancer InstituteEarly P1C (39)
Anastrozole
Prostate Carcinoma
OHSU Knight Cancer InstituteEarly P1C (39)
Atezolizumab
Prostate Carcinoma
OHSU Knight Cancer InstituteEarly P1C (39)
Bicarbonate Ion
Prostate Carcinoma
Robert Flavell, MD, PhDEarly P1C (39)
Capecitabine
Prostate Carcinoma
OHSU Knight Cancer InstituteEarly P1C (39)
Cobimetinib
Prostate Carcinoma
OHSU Knight Cancer InstituteEarly P1C (39)
Entrectinib
Prostate Carcinoma
OHSU Knight Cancer InstituteEarly P1C (39)
Eribulin
Prostate Carcinoma
OHSU Knight Cancer InstituteEarly P1C (39)
Hyaluronidase Zzxf
Prostate Carcinoma
OHSU Knight Cancer InstituteEarly P1C (39)
Showing 51 to 100 of 108 assets
PreviousPage 2 of 3Next